The European Commission has approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic Urothelial Carcinoma.
Nivolumab in combination with cisplatin and gemcitabine has now become the first concurrent immunotherapy-chemotherapy approved for the treatment of adults with unresectable or metastatic urothelial cancer in the first-line setting within the European Union.
Read the full press release:
https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx
Swiss Approval
